HFS
MRNA icon

HBC Financial Services’s Moderna MRNA Stock Holding History

HBC Financial Services’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$0 Hold
5
– – ﹤0.01% 193
2024
Q3 		$0 Sell
5
-10
-67% -$918 ﹤0.01% 187
2024
Q2 		$1K Hold
15
– – ﹤0.01% 152
2024
Q1 		$1K Hold
15
– – ﹤0.01% 153
2023
Q4 		$1K Hold
15
– – ﹤0.01% 154
2023
Q3 		$1K Hold
15
– – ﹤0.01% 162
2023
Q2 		$1K Hold
15
– – ﹤0.01% 155
2023
Q1 		$2K Hold
15
– – ﹤0.01% 159
2022
Q4 		$2K Hold
15
– – ﹤0.01% 144
2022
Q3 		$1K Hold
15
– – ﹤0.01% 154
2022
Q2 		$2K Hold
15
– – ﹤0.01% 155
2022
Q1 		$2K Hold
15
– – ﹤0.01% 148
2021
Q4 		$3K Hold
15
– – ﹤0.01% 146
2021
Q3 		$4K Buy
+15
New +$5.53K ﹤0.01% 126

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $653B AUM 32.41% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return